Eculizumab in secondary atypical haemolytic uraemic syndrome. - Wikidata - awgldk - TriplyDB

Eculizumab in secondary atypical haemolytic uraemic syndrome.

Eculizumab in secondary atypical haemolytic uraemic syndrome.

http://www.wikidata.org/entity/Q33620588

about

Biological Agents and Therapeutic Plasma Exchange: Can They Coexist in the Future?

P2860

Q47800187-9AE1A0E8-5EF9-4305-86A6-4898EF80302F

P2860

Eculizumab in secondary atypical haemolytic uraemic syndrome.

http://www.wikidata.org/entity/Q33620588

description

2017 nî lūn-bûn

@nan

2017 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2017 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

name

Eculizumab in secondary atypical haemolytic uraemic syndrome.

@ast

Eculizumab in secondary atypical haemolytic uraemic syndrome.

@en

type

label

Eculizumab in secondary atypical haemolytic uraemic syndrome.

@ast

Eculizumab in secondary atypical haemolytic uraemic syndrome.

@en

prefLabel

Eculizumab in secondary atypical haemolytic uraemic syndrome.

@ast

Eculizumab in secondary atypical haemolytic uraemic syndrome.

@en

P1433

Q33620588-70ACC950-6AAD-4830-860E-08E886BDB330

P1476

Q33620588-11EA7EE4-B85C-4165-8A76-EF2C5CCA2A84

P2093

Q33620588-0218110A-A9ED-420F-97FC-4A60AFE0757A

Q33620588-09A27B2E-28E4-42C7-9C73-896528C1BC54

Q33620588-112727C2-319A-42A1-BFE9-0504C31EF7FA

Q33620588-12BA5F76-FD35-4E37-815A-E0B2536FF916

Q33620588-17049434-BA92-4527-9438-2E25CAEB6C97

Q33620588-1896B8B4-6F75-4467-A6F4-4B20B6F13930

Q33620588-1E1331F2-601D-468A-A3D9-97A4414DE9FC

Q33620588-2EB5C035-37F4-4404-AE43-571D8CB3B7A3

Q33620588-44AEF0A3-33E6-4469-B987-DFA6B0CFBF9A

Q33620588-44D2722F-CCC9-4B8C-A71D-52745EFA22BD

P2860

Q33620588-065A250E-7454-4685-964F-C31A30008603

Q33620588-0908C4FC-3A06-4D32-8686-63F69AB18D9E

Q33620588-0BBA270D-51B5-436A-81C4-D3201824220D

Q33620588-0F633954-0BF7-4489-AFC1-7452947AF6EE

Q33620588-0FDF4D34-8B4C-4D6F-9C3C-C1F52A8C9496

Q33620588-135B86A2-64F1-438D-9707-9924735D2F62

Q33620588-14EA9229-B29C-405B-B80F-9645743E8016

Q33620588-2404ACE4-175A-4139-AB2B-CE45A1C7414E

Q33620588-25B70F53-A8BA-434D-8C2F-A7728E4138C2

Q33620588-260FCBC5-5558-40AE-8A03-329FAE521AA7

P304

Q33620588-FC0C70FA-5169-4AB5-9323-5D2963EB7AE6

P31

Q33620588-ACC8D1C7-3F75-4EA5-A15C-FD3F580FC2BB

P356

Q33620588-57F94F40-9DD7-4145-9053-6BD97712B15A

P407

Q33620588-920544F8-6B9D-492D-913A-FB0348127B81

P433

Q33620588-58AE17ED-CAEC-4311-9B06-829C07C2CA5E

P478

Q33620588-4011C347-5DC2-4B07-953D-3A3398C35B9A

P50

Q33620588-38291E90-8A24-4837-A955-607678B0CCAB

Q33620588-63CD5DB3-A249-4421-B5D9-8D5CF44020C7

Q33620588-9074EBCD-90BC-4243-895A-D0B602E3D503

Q33620588-E8A40121-E888-4A1F-B09C-F729543256F6

P577

Q33620588-8E1CA148-5210-4AE8-9D3D-FC698A0DEDF8

P698

Q33620588-798C85C1-6C5B-4296-BEBE-5A7C543CA923

P932

Q33620588-4098FCAD-D03E-43C0-B47E-D7CE98A28BBF

P356

P1433

Nephrology Dialysis Transplantation

P1476

Eculizumab in secondary atypical haemolytic uraemic syndrome.

@en

P2093

Alba García

http://www.w3.org/2001/XMLSchema#string

Ana Jarque

http://www.w3.org/2001/XMLSchema#string

Ana María Romera

http://www.w3.org/2001/XMLSchema#string

Ana Ávila

http://www.w3.org/2001/XMLSchema#string

Antía López

http://www.w3.org/2001/XMLSchema#string

Carolina Fuentes

http://www.w3.org/2001/XMLSchema#string

Carolina Gracia-Iguacel

http://www.w3.org/2001/XMLSchema#string

Cristina Rabasco

http://www.w3.org/2001/XMLSchema#string

Elena Román

http://www.w3.org/2001/XMLSchema#string

Emi Arjona

http://www.w3.org/2001/XMLSchema#string

P2860

Alternative pathway of complement in children with diarrhea-associated hemolytic uremic syndrome.

Atypical haemolytic uraemic syndrome with underlying glomerulopathies. A case series and a review of the literature

Eculizumab in severe Shiga-toxin-associated HUS

Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis

Shiga toxin activates complement and binds factor H: evidence for an active role of complement in hemolytic uremic syndrome

Pandemic H1N1 influenza A infection and (atypical) HUS--more than just another trigger?

Thrombotic thrombocytopenic purpura in the setting of systemic sclerosis.

Complement activation: the missing link between ADAMTS-13 deficiency and microvascular thrombosis of thrombotic microangiopathies.

Drug-induced thrombotic microangiopathy.

A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders.

P304

466-474

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/NDT/GFW453

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

32

http://www.w3.org/2001/XMLSchema#string

P50

Santiago Rodriguez de Córdoba

Enrique Morales

Luis F Quintana

P577

2017-02-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28339660

http://www.w3.org/2001/XMLSchema#string

P932

5410989

http://www.w3.org/2001/XMLSchema#string